EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Propositive follow‐up: Long‐term immune responses to the 4CMenB and MenACWY vaccines in people living with HIV

Alberto San Francisco Ramos iD, Catherine Isitt, Shehnaz Athaide, Shamez N Ladhani, Nicholas J Andrews, Kelly Townsend-Payne, Ann Holland, Jennifer Louth, Ray Borrow, Paul T Heath, Catherine A Cosgrove

HIV Medicine · 2024

DOI: 10.1111/hiv.13586 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, 2024. Verfasst von Alberto San Francisco Ramos und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Paediatric and Neonatal Infection, Vaccine Institute, St George's University of London, London, UK. Hauptthemen laut MEDLINE: Meningococcal Vaccines, Meningococcal Infections, HIV Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

People living with HIV have an increased risk of meningococcal disease. The Propositive trial evaluated co‐administration of two doses of a four‐component recombinant protein‐based MenB vaccine (4CMenB) and a quadrivalent conjugate polysaccharide MenACWY vaccine (MenACWY‐CRM197) given 1 month apart in people with HIV. The follow‐up trial assessed the immunogenicity of these vaccines at 1.5 and 2.5 years after primary vaccination.

Methods

Participants who completed the parent Propositive trial were invited to the follow‐up study. Immunogenicity analysis was performed at 18 and 30 months after primary vaccination. Primary outcome measures were serum bactericidal antibody (SBA) geometric mean titres (GMTs) against three MenB reference strains and the proportion of participants maintaining a protective SBA titre of ≥4 at 18 and 30 months. Secondary outcome measures were SBA GMTs against MenA, C, W, and Y serogroups and the proportion of participants maintaining a protective SBA titre of ≥8 at 18 and 30 months. The trial is registered with Clinicaltrials.gov (NCT042394300).

Results

A total of 40 participants aged 22–47 years were enrolled. Geometric mean titres waned by 18 and 30 months but remained higher than pre‐vaccination for all MenB strains and MenA, C, W, and Y. In total, 75%–85% of participants retained protective SBA titres by 30 months against individual MenB strains, whereas 68.8% of patients retained protective antibody titres against all three MenB strains. Antibodies against MenC waned more rapidly than did those against MenA, W, and Y. The proportion of participants with protective titres against MenC at 30 months was also lower (46.9%) than that with protective titres against MenA (87.5%), W (78.1%), and Y (87.5%).

Conclusions

Immune responses against MenB in our cohort of people living with HIV at 2.5 years of follow‐up were reassuring, with 68.8% of participants retaining protection against all three reference strains. However, responses against MenC were lower than those against MenA, W, and Y serogroups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Meningococcal VaccinesMeningococcal InfectionsHIV InfectionsHumansFollow-Up StudiesAntibodies, BacterialImmunityVaccines, Conjugate

Stichwörter der Autor:innen

HIVlong-term immunogenicitymeningococcal diseasemeningococcal vaccinationvaccines

Substanzen

MenACWYMeningococcal VaccinesAntibodies, BacterialVaccines, Conjugate

Autor:innen und Institutionen

  • Centre for Paediatric and Neonatal Infection, Vaccine Institute, St George's University of London, London, UK.
  • United Kingdom Health Security Agency (UKHSA), London, UK.
  • UKHSA Vaccine Evaluation Unit, Manchester Royal Infirmary Oxford Road, Manchester, UK.

ORCID-Profile: Alberto San Francisco Ramos

Förderung

  • GlaxoSmithKline

Zitieren

APA

San Francisco Ramos, A., Isitt, C., Athaide, S., Ladhani, S. N., Andrews, N. J., Townsend-Payne, K., Holland, A., Louth, J., Borrow, R., Heath, P. T., & Cosgrove, C. A. (2024). Propositive follow‐up: Long‐term immune responses to the 4CMenB and MenACWY vaccines in people living with HIV. HIV Medicine. https://doi.org/10.1111/hiv.13586

Vancouver

San Francisco Ramos A, Isitt C, Athaide S, Ladhani SN, Andrews NJ, Townsend-Payne K, et al. Propositive follow‐up: Long‐term immune responses to the 4CMenB and MenACWY vaccines in people living with HIV. HIV Medicine. 2024. doi:10.1111/hiv.13586

BibTeX
@article{SanFranciscoRamos2024,
  author = {San Francisco Ramos, Alberto and Isitt, Catherine and Athaide, Shehnaz and Ladhani, Shamez N and Andrews, Nicholas J and Townsend-Payne, Kelly and Holland, Ann and Louth, Jennifer and Borrow, Ray and Heath, Paul T and Cosgrove, Catherine A},
  title = {Propositive follow‐up: Long‐term immune responses to the 4CMenB and MenACWY vaccines in people living with HIV},
  journal = {HIV Medicine},
  year = {2024},
  doi = {10.1111/hiv.13586}
}
Kostenlos starten →